Cardiovascular and musculskeletal co-morbidities in patients with alpha 1 antitrypsin deficiency

James M. Duckers, Dennis J. Shale, Robert A. Stockley, Nichola S. Gale, Bronwen A J Evans, John R. Cockcroft, Charlotte E. Bolton*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    39 Citations (Scopus)

    Abstract

    Background: Determining the presence and extent of co-morbidities is fundamental in assessing patients with chronic respiratory disease, where increased cardiovascular risk, presence of osteoporosis and low muscle mass have been recognised in several disease states. We hypothesised that the systemic consequences are evident in a further group of subjects with COPD due to Alpha-1 Antitrypsin Deficiency (A1ATD), yet are currently under-recognised.Methods: We studied 19 patients with PiZZ A1ATD COPD and 20 age, sex and smoking matched controls, all subjects free from known cardiovascular disease. They underwent spirometry, haemodynamic measurements including aortic pulse wave velocity (aPWV), an independent predictor or cardiovascular risk, dual energy X-ray absorptiometry to determine body composition and bone mineral density.Results: The aPWV was greater in patients: 9.9(2.1) m/s than controls: 8.5(1.6) m/s, p = 0.03, despite similar mean arterial pressure (MAP). The strongest predictors of aPWV were age, FEV1% predicted and MAP (all p < 0.01). Osteoporosis was present in 8/19 patients (2/20 controls) and was previously unsuspected in 7 patients. The fat free mass and bone mineral density were lower in patients than controls (p < 0.001).Conclusions: Patients with A1ATD related COPD have increased aortic stiffness suggesting increased risk of cardiovascular disease and evidence of occult musculoskeletal changes, all likely to contribute hugely to overall morbidity and mortality.

    Original languageEnglish
    Article number173
    JournalRespiratory Research
    Volume11
    DOIs
    Publication statusPublished - 7 Dec 2010

    Fingerprint Dive into the research topics of 'Cardiovascular and musculskeletal co-morbidities in patients with alpha 1 antitrypsin deficiency'. Together they form a unique fingerprint.

    Cite this